Afanat 30mg

About Afanat 30mg

Afanat 30mg contains Afatinib Dimaleate, a second-generation tyrosine kinase inhibitor (TKI) developed for the targeted treatment of non-small cell lung cancer (NSCLC). Manufactured by Natco Pharma Ltd., this oral tablet works by irreversibly blocking specific epidermal growth factor receptor (EGFR) mutations that drive cancer cell growth and proliferation. By inhibiting these cellular pathways, Afanat helps slow tumour progression in patients with EGFR mutation-positive NSCLC, particularly those with deletion 19 or exon 21 substitution mutations. Like other life-saving oncology medications such as Acabrunat 100mg, Afanat represents an important advancement in precision cancer therapy. For patients requiring alternative dosing options, Afanat 20mg may be prescribed based on individual tolerance and treatment response.

Dosage & Usage

The standard recommended dose of Afanat is 30mg taken orally once daily, at least one hour before or two hours after food consumption. This medication should be taken at the same time each day with a full glass of water to maintain consistent blood levels. Do not exceed 40mg daily without explicit medical guidance. Treatment typically continues until disease progression or unacceptable toxicity occurs. Dose reduction to 20mg may be necessary if adverse effects such as severe diarrhoea or skin reactions develop. Never crush, chew, or split the tablets, as this can alter the drug's absorption and effectiveness. Patients should swallow tablets whole and maintain regular monitoring appointments to assess treatment response.

Who Is It For?

Afanat 30mg is specifically indicated for adults diagnosed with metastatic NSCLC whose tumours harbour EGFR-activating mutations as detected by validated testing methods. It is particularly beneficial as first-line therapy in patients with newly diagnosed EGFR mutation-positive disease or as second-line treatment following chemotherapy. This medication is not suitable for patients with severe liver impairment, those with interstitial lung disease, or women who are pregnant or breastfeeding. Similar to other targeted cancer therapies like Celgem 200mg, Afanat requires careful patient selection based on molecular testing and comprehensive health assessment. Patients must undergo EGFR mutation testing before initiating treatment to confirm appropriate candidacy.

Why Buy From SafeRxPills?

SafeRxPills delivers genuine WHO-GMP certified Afanat 30mg directly to patients in the USA, UK, Australia, and Canada with complete discretion. Your medication arrives in plain, unmarked packaging within 7-14 business days, ensuring both privacy and authenticity. We source exclusively from licensed manufacturers like Natco Pharma Ltd., guaranteeing pharmaceutical-grade quality at accessible prices. Our secure ordering platform and professional customer support team ensure a seamless experience from prescription verification through delivery, making essential cancer treatments available when you need them most.